Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study-Reference-Cited by-同舟云学术

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Published:2021-07-27 Issue:22 Volume:127 Page:4198-4212
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lonial Sagar¹^ORCID,Lee Hans C.²,Badros Ashraf³^ORCID,Trudel Suzanne⁴,Nooka Ajay K.¹^ORCID,Chari Ajai⁵^ORCID,Abdallah Al‐Ola⁶,Callander Natalie⁷,Sborov Douglas⁸,Suvannasankha Attaya⁹,Weisel Katja¹⁰,Voorhees Peter M.¹¹,Womersley Lynsey¹²,Baron January¹³,Piontek Trisha¹³,Lewis Eric¹⁴,Opalinska Joanna¹³,Gupta Ira¹³,Cohen Adam D.¹⁵

Affiliation:

1. Winship Cancer InstituteEmory University Atlanta Georgia

2. Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston Texas

3. Greenebaum Cancer Center, Bone Marrow Transplant Program University of Maryland at Baltimore Baltimore Maryland

4. Princess Margaret Cancer Center Toronto Ontario Canada

5. Icahn School of Medicine at Mount Sinai New York New York

6. University of Kansas Cancer Center Fairway Kansas

7. Carbone Cancer Center University of Wisconsin Madison Wisconsin

8. Huntsman Cancer InstituteUniversity of Utah Salt Lake City Utah

9. Indiana University Cancer Center Indianapolis Indiana

10. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology University Medical Center of Hamburg‐Eppendorf Hamburg Germany

11. Levine Cancer InstituteAtrium Health Charlotte North Carolina

12. GlaxoSmithKline Stockley Park United Kingdom

13. GlaxoSmithKline Upper Providence Pennsylvania

14. GlaxoSmithKline Research Triangle Park North Carolina

15. Abramson Cancer Center, University of Pennsylvania Philadelphia Pennsylvania

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Cancer Research,Oncology

Link